Conclusions drawn from the pancreatic (or islet) clamp technique (suppression of endogenous insulin, glucagon, and growth hormone secretion with somatostatin and replacement of basal hormone levels by intravenous infusion) are critically dependent on the biological appropriateness of the selected doses of the replaced hormones. To assess the appropriateness of representative doses we infused saline alone, insulin (initially 0.20 mU ⅐ kg Ϫ1 ⅐ min Ϫ1 ) alone, glucagon (1.0 ng ⅐ kg Ϫ1 ⅐ min Ϫ1 ) alone, and growth hormone (3.0 ng ⅐ kg Ϫ1 ⅐ min Ϫ1 ) alone intravenously for 4 h in 13 healthy individuals. That dose of insulin raised plasma insulin concentrations approximately threefold, suppressed glucose production, and drove plasma glucose concentrations down to subphysiological levels (65 Ϯ 3 mg/dl, P Ͻ 0.0001 vs. saline), resulting in nearly complete suppression of insulin secretion (P Ͻ 0.0001) and stimulation of glucagon (P ϭ 0.0059) and epinephrine (P ϭ 0.0009) secretion. An insulin dose of 0.15 mU ⅐ kg Ϫ1 ⅐ min Ϫ1 caused similar effects, but a dose of 0.10 mU ⅐ kg Ϫ1 ⅐ min Ϫ1 did not. The glucagon and growth hormone infusions did not alter plasma glucose levels or those of glucoregulatory factors. Thus, insulin "replacement" doses of 0.20 and even 0.15 mU ⅐ kg Ϫ1 ⅐ min Ϫ1 are excessive, and conclusions drawn from the pancreatic clamp technique using such doses may need to be reassessed.
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octreotide; pancreatic clamp THE PANCREATIC (OR ISLET) CLAMP TECHNIQUE involves the infusion of somatostatin (or the somatostatin analog octreotide) to suppress endogenous insulin, glucagon, and growth hormone secretion and replacement of basal levels of these hormones by intravenous infusion (1, 3, 12, 23, 24, 25, 27, 33) . It has been used to assess the metabolic roles of these hormones and led, for example, to the conclusion that glucagon normally supports the postabsorptive plasma glucose concentration, since plasma glucose levels decreased when somatostatin and insulin were infused and glucagon was not replaced (27) . Although there is a body of evidence that supports that view (26) , much of that evidence is open to alternative interpretations. Clearly, such conclusions are critically dependent on the biological appropriateness of the selected doses of the replaced hormones.
The glycemic response to infusion of somatostatin is biphasic with an initial decrease in glucose production (19, 28, 31) and the plasma glucose concentration (20, 28, 31) followed by an increase in glucose production (19, 28, 31) and the plasma glucose concentration (20, 28, 31) in healthy humans. Like native somatostatin, infusion of the more potent somatostatin analog octreotide suppresses plasma insulin, glucagon, and growth hormone concentrations in humans (16) .
Insulin has been infused peripherally in doses of 0.14 (25), 0.15 (19) , 0.20 (1, 27) , and 0.24 (24) mU⅐kg Ϫ1 ⅐min Ϫ1 in humans [and intraportally in a dose of 0.25 mU⅐kg Ϫ1 ⅐min Ϫ1 in dogs (12) ] to replace basal insulin levels during the infusion of somatostatin. In the human studies peripheral insulin concentrations were intended to be raised approximately twofold on the basis of the rationale that, given ϳ50% extraction of insulin by the liver, it was necessary to double peripheral insulin concentrations to replace basal hepatic portal venous insulin levels, which were thought to be the sole determinant of endogenous glucose production and thus the postabsorptive plasma glucose concentration. However, that rationale could be questioned given more recent evidence that some of the effect of insulin to reduce endogenous glucose production is indirect, i.e., initially extrahepatic (and extrarenal), on adipose tissue to reduce nonesterified fatty acid levels (2), on muscle to reduce gluconeogenic precursor flux to the liver (and kidneys), on pancreatic ␣-cells to reduce glucagon secretion, and on the brain to increase parasympathetic firing to the liver (4) and thus the result of peripheral insulin actions. The relative contributions of the direct and indirect actions continue to be debated (6, 11) . Clearly, it is important that insulin not be substantially overreplaced during pancreatic clamps. To our knowledge, the effects of putative basal insulin replacement doses alone (in the absence of somatostatin) in healthy humans has not been reported. Lewis et al. (18) (12) ] to replace basal glucagon levels during the infusion of somatostatin. The use of the higher doses, infused peripherally, in the human studies was based on the assumption of ϳ25% extraction of glucagon by the liver and the premise that only portal levels are relevant to the actions of glucagon on glucose production. Clearly, it is important that glucagon not be substantially overreplaced during pancreatic clamps.
Growth hormone has been infused peripherally in doses of 2.0 (25), 3.0 (1), and 4.7 (24) ng⅐kg Ϫ1 ⅐min Ϫ1 in humans to replace basal growth hormone levels during the infusion of somatostatin. Growth hormone levels were held constant with the 3.0 ng⅐kg Ϫ1 ⅐min Ϫ1 dose (1); they appeared to be somewhat lower than baseline with the 2.0 ng⅐kg Ϫ1 ⅐min Ϫ1Ϫ dose (25) . Since the plasma glucose-raising action of growth hormone is delayed for several hours (22) , the need to replace growth hormone could be questioned. However, growth hormone has an initial insulin-like effect (22) . To assess the appropriateness of representative doses of insulin, glucagon, and growth hormone to produce putative replacement of basal hormone levels, we infused saline alone, insulin (initially 0.20 mU ⅐ kg Ϫ1 ⅐ min Ϫ1 ) alone, glucagon (1.0 ng ⅐ kg Ϫ1 ⅐ min Ϫ1 ) alone, or growth hormone (3.0 ng ⅐ kg Ϫ1 ⅐ min Ϫ1 ) alone intravenously, in random sequence, for 4 h without somatostatin in healthy adults. We reasoned that if these were truly basal replacement doses they would have little effect on glucose kinetics and plasma glucose concentrations. Experimental design. All studies were performed in the morning after an overnight fast. Subjects were in the supine position throughout. To permit estimation of glucose kinetics, a primed (22.5 mol/ kg), constant (0.25 mol ⅐ kg Ϫ1 ⅐ min Ϫ1 ), intravenous infusion of [6,6- 2 H2]glucose was started at Ϫ180 min and continued through 300 min. Arterialized venous plasma samples, from a hand vein with that hand kept in a ϳ55°C plexiglas box, were drawn at 15-min intervals from Ϫ30 to 300 min for glucose concentration and isotope enrichment determinations and from Ϫ15 to 240 min and at 270 and 300 min for the other analytes detailed below. Heart rates and blood pressures were determined at the same time points, and the electrocardiogram was monitored throughout.
METHODS

Subjects
Intravenous infusions of saline, insulin (0.20 mU⅐kg
), or growth hormone (3.0 ng⅐kg Ϫ1 ⅐min Ϫ1 ) were administered from 0 to 240 min in random sequence. Subsequently, a subset (n ϭ 10) of the subjects was restudied with infusion of insulin in a dose of 0.10 mU ⅐ kg Ϫ1 ⅐ min Ϫ1 from 0 to 120 min and 0.15 mU ⅐ kg Ϫ1 ⅐ min Ϫ1 from 120 to 240 min. Hormone infusates were prepared in saline containing 0.5 g/dl albumin.
Biochemical analytical methods. Plasma glucose concentrations were measured using a glucose oxidase method (Yellow Springs Analyzer 2; Yellow Springs Instruments, Yellow Springs, OH). Plasma insulin (17), C-peptide (17), glucagon (7), pancreatic polypeptide (10), growth hormone (29) , and cortisol (8) were measured with radioimmunoassays. The insulin, C-peptide, glucagon, and pancreatic polypeptide assays were performed with materials purchased from Linco Research (St. Louis, MO) and the cortisol assay with materials purchased from Diasorin (Stillwater, MN). An antibody provided by the National Institutes of Health was used for the growth hormone assay. Plasma epinephrine and norepinephrine were measured with a single isotope derivative (radioenzymatic) method (30) . Serum nonesterified fatty acids (15) and blood lactate (21) were measured with enzymatic techniques.
Glucose tracer methodology. Plasma proteins were precipitated with ice-cold acetone and lipids extracted with hexane. The aqueous phase was dried by Speed-Vac centrifugation (Savant Instruments, Farmingdale, NY). Samples were derivatized with 10% heptafluorobutyric (HFB) anhydride in ethyl acetate (30 min at 70°C). The tracer-to-tracee ratio (TTR) of HFB-glucose was measured by gas chromatography-mass spectrometry using electron impact ionization (ions of mass/charge ratio 519 and 521 for natural and [6,6- 2 H2]glucose, respectively) on an Agilent 5973 system equipped with a 30 m ϫ 0.32 mm HP-5MS column. Instrument response was calibrated using prepared glucose standards of known isotopic enrichment. Non-steady-state kinetic analysis to obtain the rates of appearance (R a) and disappearance (Rd) of plasma glucose was performed (28, 30) as follows:
where Ra(t) and Rd(t) are the rates of appearance and disappearance of unlabeled glucose, respectively, as functions of time
; pV is the effective glucose volume of distribution (assumed to be 40 ml/kg); C is the concentration of unlabeled glucose (mmol/l); E is the isotopic enrichment (TTR); dE/dt is the rate of change of TTR; and dC/dt is the rate of change of unlabeled glucose concentration. Plasma glucose concentrations and TTR values were smoothed using a loess local polynomial smoothing function (Mathcad 11; Mathsoft Engineering & Education, Cambridge, MA) prior to calculations and to obtain the rates of change of TTR and concentration.
Statistical methods. Data are expressed as means Ϯ SE, except where the standard deviation is specified. Condition and time-related data were analyzed by mixed-model repeated-measures analysis of variance. The Proc Mixed module of the SAS statistical package version 8.2 was used. P values Ͻ0.05 were considered to indicate significant differences.
RESULTS
Plasma concentrations of infused hormones.
During saline infusion, plasma insulin concentrations tended to decline (Fig. 1) , as did plasma glucose concentrations (Fig. 2) . Insulin infusion in a dose of 0.20 mU⅐kg Ϫ1 ⅐min Ϫ1 raised plasma insulin concentrations approximately threefold (P Ͻ 0.0001 vs. saline; Fig. 1 ) from 3.8 Ϯ 0.7 U/ml at 0 min to 13.8 Ϯ 2.1 U/ml at 30 min and 11.8 Ϯ 2.2 U/ml at 240 min. A dose of 0.10 mU⅐kg Ϫ1 ⅐min Ϫ1 raised plasma insulin concentrations approximately twofold (from 3.5 Ϯ 0.5 U/ml at 0 min to 7.5 Ϯ 1.0 U/ml at 120 min, P ϭ 0.0005; Fig. 1 ). A dose of 0.15 mU⅐kg Ϫ1 ⅐min Ϫ1 raised plasma insulin concentrations further (to 10.2 Ϯ 1.4 U/ml at 240 min, P Ͻ 0.0001; Fig. 1 ). Glucagon infusion (1.0 ng⅐kg Ϫ1 ⅐min Ϫ1 ) appeared to raise plasma glucagon concentrations slightly, although not significantly (Fig. 1) . The levels were 113 Ϯ 5 pg/ml at 0 min and 131 Ϯ 6 pg/ml at 240 min. Growth hormone infusion (3.0 ng⅐kg Ϫ1 ⅐min) did not raise plasma growth hormone concentrations (Fig. 1) . The levels were 3.9 Ϯ 3.0 ng/ml at 0 min and 3.2 Ϯ 1.0 ng/ml at 240 min.
Plasma glucose concentrations and glucose kinetics. Insulin infusion in a dose of 0.20 mU⅐kg Ϫ1 ⅐min Ϫ1 lowered plasma glucose concentrations sharply (P Ͻ 0.0001 vs. saline; Fig. 2 ) from 88 Ϯ 2 mg/dl at 0 min to 72 Ϯ 4 mg/dl at 60 min, 71 Ϯ 3 mg/dl at 120 min, and 65 Ϯ 3 mg/dl at 240 min. Insulin infusion in a dose of 0.10 mU⅐kg Ϫ1 ⅐min Ϫ1 lowered plasma glucose concentrations (from 88 Ϯ 2 to 76 Ϯ 1 mg/dl at 120 min; P ϭ 0.0158) and in a dose of 0.15 mU⅐kg Ϫ1 ⅐min Ϫ1 lowered plasma glucose concentrations further (to 67 Ϯ 2 mg/dl at 240 min, P Ͻ 0.0001; Fig. 2 ). Insulin infusion in a dose of 0.20 mU⅐kg Ϫ1 ⅐min Ϫ1 decreased the relative (to baseline) R a initially (P ϭ 0.0086 vs. saline; Table 1 ). Thus, glucose R a was lower than glucose R d , and the plasma glucose concentrations declined. Then, glucose R a increased and matched plasma R d . A similar, but smaller, glucose kinetic pattern appeared to develop initially during insulin infusions in lower doses (Table l), although that did not reach statistical significance (P ϭ 0.0562). Glucose R a and R d drifted downward during infusion of saline (Table l) . They were unaltered compared with saline during infusions of glucagon and of growth hormone in the doses studied (data not shown). Thus, glucose R a and R d time course profiles were superimposable during infusions of saline, glucagon, and growth hormone.
Neuroendocrine and other metabolic responses. As plasma glucose concentrations decreased during infusion of insulin in a dose of 0.20 mU⅐kg Ϫ1 ⅐min Ϫ1 , plasma C-peptide concentrations decreased sharply (P Ͻ 0.0001; Fig. 3 ) from 1.1 Ϯ 0.1 ng/ml at 0 min to 0.7 Ϯ 0.1 ng/ml at 60 min, 0.4 Ϯ 0.1 ng/ml at 120 min, and 0.3 Ϯ 0.0 ng/ml at 240 min. Indeed, as plasma glucose declined within the physiological range during infusion of insulin in a dose of 0.10 mU⅐kg Ϫ1 ⅐min Ϫ1 , plasma C-peptide concentrations also declined (from 1.3 Ϯ 0.1 ng/ml at 0 min to 0.7 Ϯ 0.1 ng/ml at 120 min, P ϭ 0.0038), and, as plasma glucose concentrations fell further during infusion of insulin in a dose of 0.15 mU⅐kg Ϫ1 ⅐min Ϫ1 , plasma C-peptide concentrations decreased further (to 0.4 Ϯ 0.0 ng/ml at 240 min, P Ͻ 0.0001; Fig. 3 ).
Decrements in plasma glucose concentrations to subphysiological levels during infusion of insulin in a dose of 0.20 mU⅐kg Ϫ1 ⅐min Ϫ1 were associated with increments in the plasma concentrations of glucagon (P ϭ 0.0059), epinephrine (P ϭ 0.0009), and pancreatic polypeptide (P Ͻ 0.0001; Fig. 3 ). Plasma glucagon levels increased from 116 Ϯ 6 pg/ml at 0 min to 144 Ϯ 10 pg/ml at 240 min, epinephrine levels from 76 Ϯ 9 to 292 Ϯ 89 pg/ml, and pancreatic polypeptide levels from 73 Ϯ 10 to 228 Ϯ 41 pg/ml. Plasma norepinephrine concentrations (data not shown) increased (P Ͻ 0.0001) from 179 Ϯ 7 to 226 Ϯ 24 pg/ml. Plasma growth hormone (P ϭ 0.0318) and cortisol (P ϭ 0.0002) concentrations also increased (Table  2) . Serum nonesterified fatty acid concentrations were suppressed (P ϭ 0.0163) from 652 Ϯ 54 mol/l at 0 min to a nadir of 237 Ϯ 59 mol/l at 90 min and then rose to 532 Ϯ 84 mol/l at 240 min (Table 3 ). Blood lactate concentrations (443 Ϯ 28 mol/l at 0 min and 634 Ϯ 112 mol/l at 240 min) increased (P ϭ 0.0117) ( Table 3) . Decrements in plasma glucose concentrations within the physiological range during infusion of insulin in a dose of 0.10 mU⅐kg Ϫ1 ⅐min Ϫ1 were not associated with increments in the plasma concentrations of glucagon, epinephrine, or pancreatic polypeptide (Fig. 3) , of growth hormone or cortisol (Table 2) , or of norepinephrine (data not shown). Serum nonesterified fatty acid concentrations remained suppressed (P ϭ 0.0463), but blood lactate concentrations tended to increase (Table 3) . On the other hand, decrements in plasma glucose concentrations to subphysiological levels during infusion of insulin in a dose of 0.15 mU⅐kg Ϫ1 ⅐min Ϫ1 were associated with increments in the plasma concentrations of glucagon (P ϭ 0.0041) and epinephrine (P ϭ 0.0094); pancreatic polypeptide appeared to increase (P ϭ 0.1185) (Fig. 3) . Growth hormone increased (P ϭ 0.0416), and cortisol tended to increase (P ϭ 0.1436) ( Table 2 ). Norepinephrine increased (P ϭ 0.0009; data not shown).
Infusions of glucagon and of growth hormone were not associated with changes in the plasma concentrations of insulin or epinephrine (Table 4) , the serum concentrations of nonesterified fatty acids, or the blood concentrations of lactate (Table 5) or any of the other measured neuroendocrine variables (data not shown).
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heart rates (P ϭ 0.0016) and slightly lower diastolic blood pressures (P ϭ 0.0275) during infusion of insulin in a dose of 0.20 mU⅐kg Ϫ1 ⅐min Ϫ1 .
DISCUSSION
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thresholds for activation of glucose counterregulatory systems, the plasma concentrations of glucagon and epinephrine, as well as those of growth hormone and cortisol, increased. Were it not for these glucose counterregulatory defenses, plasma glucose concentrations would undoubtedly have fallen to even lower levels. Furthermore, infusion of insulin in a lower dose of 0.15 mU⅐kg Ϫ1 ⅐min Ϫ1 also drove plasma glucose concentrations down to subphysiological levels and activated glucose counterregulatory systems. Clearly, conclusions drawn from use of the pancreatic clamp technique with such doses that might be critically dependent on an excessive insulin replacement dose, including our own (27) , need to be reassessed in light of these findings.
The lowest insulin dose tested, 0.10 mU⅐kg Ϫ1 ⅐min Ϫ1 , raised plasma insulin concentrations approximately twofold and lowered plasma glucose concentrations within the physiological range. As a result, endogenous insulin secretion, as assessed by plasma C-peptide concentrations, decreased. It also suppressed lipolysis as assessed by serum nonesterified fatty acid concentrations. Clearly, that too is a biologically active dose. However, over the time frame studied, unlike both of the higher doses, it did not cause subphysiological glucose levels and did not suppress insulin secretion completely. It would likely have had less of a plasma glucose-lowering effect in the absence of endogenous insulin secretion. Thus, a peripheral intravenous insulin dose of 0.10 mU⅐kg Ϫ1 ⅐min Ϫ1 would appear to be a more appropriate dose for portal venous insulin replacement with the pancreatic clamp technique in humans.
The glucagon and growth hormone doses tested did not alter plasma glucose concentrations or any of the measured glucoregulatory factors. Infusion of glucagon in a dose of 1.0 ng⅐kg Ϫ1 ⅐min Ϫ1 did not raise plasma glucagon concentrations significantly. Mean values at 240 min were only 16% higher than those prior to glucagon infusion. Growth hormone infusion in a dose of 3.0 ng⅐ kg Ϫ1 ⅐min Ϫ1 did not alter plasma growth hormone concentrations measurably. However, we have no measure of any effects of these infusions on endogenous glucagon or growth hormone secretion. In any event, these doses are not excessive. Indeed, they are somewhat low.
Insulin lowered plasma glucose concentrations by suppressing glucose production rather than by stimulating glucose utilization. The glucose R a decreased initially and was lower than the glucose R d , and the plasma glucose concentrations, therefore, decreased. Then glucose R a increased to match R d , and the plasma glucose levels plateaued. The glucose kinetic method we used underestimates glucose R a and R d (9, 15) even during infusions of low doses of insulin (12) . Therefore, our results are reported as those relative to baseline rather than as absolute rates. The observed decrement in glucose R a was small compared with that during euglycemic clamps with similar doses of insulin (15) , but the latter may well have also included a suppressive effect of glucose per se. Glucose turnover rates drifted downward during infusion of saline and were similar, with glucose R a and R d superimposable, during infusion of saline, of glucagon, and of growth hormone. Thus, in the doses tested, neither glucagon nor growth hormone raised plasma glucose concentrations.
These data confirm several principles of the physiology of glucose counterregulation, the mechanisms that normally prevent or rapidly correct clinical hypoglycemia, in humans (5, 13). First, the glycemic threshold for decrements in insulin secretion as plasma glucose concentrations decline lies within the postabsorptive plasma glucose concentration range. Second, the glycemic thresholds for increments in the secretion of the glucose counterregulatory hormones (glucagon, epinephrine, growth hormone, and cortisol) lie just below the physiological range. Third, in the setting of intact glucose counterregulatory systems, plasma glucose concentrations plateau at levels just below the physiological range and at levels higher than those required to produce symptoms of hypoglycemia despite ongoing hyperinsulinemia sufficient to decrease plasma glucose levels. In essence, a new steady state is established at plasma glucose concentrations low enough to maintain activation of glucose counterregulatory systems but higher than the glycemic threshold for symptoms of hypoglycemia.
In summary, these data indicate that putative basal intravenous insulin replacement doses of 0. 20 
